These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33165946)

  • 1. Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study.
    Yasuno F; Minami H; Hattori H;
    Int J Geriatr Psychiatry; 2021 Apr; 36(4):598-605. PubMed ID: 33165946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study.
    Yasuno F; Minami H
    Int J Geriatr Psychiatry; 2021 Aug; 36(8):1274-1283. PubMed ID: 33594726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Season of birth and vulnerability to the pathology of Alzheimer's disease: an in vivo positron emission tomography study.
    Yasuno F; Minami H;
    Psychogeriatrics; 2022 Jul; 22(4):445-452. PubMed ID: 35474398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction effect of Alzheimer's disease pathology and education, occupation, and socioeconomic status as a proxy for cognitive reserve on cognitive performance: in vivo positron emission tomography study.
    Yasuno F; Minami H; Hattori H;
    Psychogeriatrics; 2020 Sep; 20(5):585-593. PubMed ID: 32285577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease.
    Tommasi NS; Gonzalez C; Briggs D; Properzi MJ; Gatchel JR; Marshall GA;
    Int J Geriatr Psychiatry; 2021 Jul; 36(7):1050-1058. PubMed ID: 33682933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
    Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
    J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of informant-based sleep reports with Alzheimer's disease pathologies.
    Shokouhi S
    Clin Interv Aging; 2019; 14():1631-1642. PubMed ID: 31571843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
    Dang M; Chen Q; Zhao X; Chen K; Li X; Zhang J; Lu J; Ai L; Chen Y; Zhang Z
    Hum Brain Mapp; 2023 Feb; 44(2):327-340. PubMed ID: 36647262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
    Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA
    J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.